English

• 

• 1. [1] A.N. Vgontzas, A. Kales, Sleep and its disorders, Annu. Rev. Med. 50 (1999) 387-400.[1] A.N. Vgontzas, A. Kales, Sleep and its disorders, Annu. Rev. Med. 50 (1999) 387-400.

  2. [2] E.E. Matthews, J. Todd Arnedt, M.S. McCarthy, L.J. Cuddihy, M.S. Aloia, Adherence to cognitive behavioral therapy for insomnia: a systematic review, Sleep Med. Rev. 17 (2013) 453-464.[2] E.E. Matthews, J. Todd Arnedt, M.S. McCarthy, L.J. Cuddihy, M.S. Aloia, Adherence to cognitive behavioral therapy for insomnia: a systematic review, Sleep Med. Rev. 17 (2013) 453-464.

  3. [3] P.K. Kondamudi, R. Malayandi, C. Eaga, D. Aggarwal, Drugs as causative agents and therapeutic agents in inflammatory bowel disease, Acta Pharm. Sin. B 5 (2013) 289-296.[3] P.K. Kondamudi, R. Malayandi, C. Eaga, D. Aggarwal, Drugs as causative agents and therapeutic agents in inflammatory bowel disease, Acta Pharm. Sin. B 5 (2013) 289-296.

  4. [4] D. Leger, V. Bayon, Societal costs of insomnia, Sleep Med. Rev. 14 (2010) 379-389.[4] D. Leger, V. Bayon, Societal costs of insomnia, Sleep Med. Rev. 14 (2010) 379-389.

  5. [5] C.R. Hopkins, ACS Chemical neuroscience molecule spotlight on suvorexant, ACS Chem. Neurosci. 3 (2012) 647-648.[5] C.R. Hopkins, ACS Chemical neuroscience molecule spotlight on suvorexant, ACS Chem. Neurosci. 3 (2012) 647-648.

  6. [6] T. Sakurai, A. Amemiya, M. Ishii, et al., Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior, Cell 92 (1998) 573-585.[6] T. Sakurai, A. Amemiya, M. Ishii, et al., Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein coupled receptors that regulate feeding behavior, Cell 92 (1998) 573-585.

  7. [7] L. de Lecea, T.S. Kilduff, C. Peyron, et al., The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 322-327.[7] L. de Lecea, T.S. Kilduff, C. Peyron, et al., The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity, Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 322-327.

  8. [8] M. Hungs, E. Mignot, Hypocretin/orexin, sleep and narcolepsy, BioEssay 23 (2001) 397-408.[8] M. Hungs, E. Mignot, Hypocretin/orexin, sleep and narcolepsy, BioEssay 23 (2001) 397-408.

  9. [9] C.D. Cox, M.J. Breslin, D.B. Whitman, et al., Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia, J. Med. Chem. 53 (2010) 5320-5332.[9] C.D. Cox, M.J. Breslin, D.B. Whitman, et al., Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia, J. Med. Chem. 53 (2010) 5320-5332.

  10. [10] C.A. Baxter, E. Cleator, M.J. Karel, et al., The first large-scale synthesis of MK-4305: a dual orexin receptor antagonist for the treatment of sleep disorder, Org. Process Res. Dev. 15 (2011) 367-375.[10] C.A. Baxter, E. Cleator, M.J. Karel, et al., The first large-scale synthesis of MK-4305: a dual orexin receptor antagonist for the treatment of sleep disorder, Org. Process Res. Dev. 15 (2011) 367-375.

  11. [11] N.A. Strotman, C.A. Baxter, M.J. Karel, et al., Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual orexin inhibitor suvorexant (MK-4305), J. Am. Chem. Soc. 133 (2011) 8362-8371.[11] N.A. Strotman, C.A. Baxter, M.J. Karel, et al., Reaction development and mechanistic study of a ruthenium catalyzed intramolecular asymmetric reductive amination en route to the dual orexin inhibitor suvorexant (MK-4305), J. Am. Chem. Soc. 133 (2011) 8362-8371.

  12. [12] I.K. Mangion, B.D. Sherry, J.J. Yin, et al., Enantioselective synthesis of a dual orexin receptor antagonist, Org. Lett. 14 (2012) 3458-3461.[12] I.K. Mangion, B.D. Sherry, J.J. Yin, et al., Enantioselective synthesis of a dual orexin receptor antagonist, Org. Lett. 14 (2012) 3458-3461.

  13. [13] C.Q. Sun, W.R. Ewing, S.A. Bolton, et al., Substituted adipic acid amides and uses thereof, WO2012125622.[13] C.Q. Sun, W.R. Ewing, S.A. Bolton, et al., Substituted adipic acid amides and uses thereof, WO2012125622.

•